Rat Anti-CCL22 Recombinant Antibody (CBFYM-0929) (CBMAB-M1078-FY)

Xu, H., Lin, S., & Huang, H. (2021). Involvement of increased expression of chemokine C–C motif chemokine 22 (CCL22)/CC chemokine receptor 4 (CCR4) in the inflammatory injury and cartilage degradation of chondrocytes. Cytotechnology, 73(5), 715-726.

Dong, Y., Gao, S., Zhang, X., Kou, J., Liu, J., Ye, T., & Shen, H. (2021). CCL17 and CCL22 induce CCR4 receptor expression and promote cytokine-induced killer cells migration. Anti-cancer Drugs.

Kimura, S., Noguchi, H., Nanbu, U., & Nakayama, T. (2021). Macrophage CCL22 expression promotes lymphangiogenesis in patients with tongue squamous cell carcinoma via IL-4/STAT6 in the tumor microenvironment. Oncology Letters, 21(5), 1-11.

Baer, C., Kimura, S., Iacobucci, I., Feith, D. J., Walter, W., Meggendorfer, M., ... & Haferlach, T. (2020). Recurrent Mutations of the CC Motif Chemokine Ligand 22 (CCL22) Define a Distinct Subgroup of Chronic Lymphoproliferative Disorder of NK Cells (CLPD-NK). Blood, 136, 19.

Ohuchi, K., Fujimura, T., Lyu, C., Amagai, R., Muto, Y., & Aiba, S. (2020). Serum CCL22 levels decreased in parallel with disease activity in CCR4‐positive mycosis fungoides treated with mogamulizumab. Dermatologic Therapy, 33(6), e14099.

Huang, Y. H., Chang, C. Y., Kuo, Y. Z., Fang, W. Y., Kao, H. Y., Tsai, S. T., & Wu, L. W. (2019). Cancer‐associated fibroblast‐derived interleukin‐1β activates protumor C‐C motif chemokine ligand 22 signaling in head and neck cancer. Cancer science, 110(9), 2783-2793.

Kashefi, S., Ahmadi, H., Omranipour, R., Mahmoodzadeh, H., Jafarnezhad-Ansariha, F., Zavareh, F. T., & Mirshafiey, A. (2019). The anti-tumoral effect of β-D-mannuronic acid (M2000) as a novel NSAID on Treg cells frequency and MMP-2, MMP-9, CCL22 and TGFβ1 gene expression in pre-surgical breast cancer patients. Iranian Journal of Allergy, Asthma and Immunology, 80-90.

Li, X., Li, D., Shi, Q., Huang, X., & Ju, X. (2019). Umbilical cord blood‑derived Helios‑positive regulatory T cells promote angiogenesis in acute lymphoblastic leukemia in mice via CCL22 and the VEGFA‑VEGFR2 pathway. Molecular medicine reports, 19(5), 4195-4204.

Wu, S., He, H., Liu, H., Cao, Y., Li, R., Zhang, H., ... & Xu, J. (2018). CC motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer. Oncoimmunology, 7(6), e1433517.

Wei, Y., Wang, T., Song, H., Tian, L., Lyu, G., Zhao, L., & Xue, Y. (2017). CC motif chemokine 22 ligand (CCL22) concentrations in sera of gastric cancer patients are related to peritoneal metastasis and predict recurrence within one year after radical gastrectomy. Journal of Surgical Research, 211, 266-278.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols